High volume screening procedures for hypobetalipoproteinemic activity in rats

Area of Science:

• Pharmacology
• Biochemistry
• Drug Discovery

Background:

• Hypercholesterolemia is a significant risk factor for cardiovascular disease.
• Developing effective hypobetalipoproteinemic agents is crucial for managing cholesterol levels.
• Existing hypocholesterolemic drugs have varying efficacy and side effect profiles.

Purpose of the Study:

• To establish a high-volume screening method for identifying novel hypobetalipoproteinemic agents.
• To evaluate the efficacy of bicyclo (2.2.2)-octyloxyaniline (U-26328) in reducing specific lipoproteins.
• To compare the activity of U-26328 against established hypocholesterolemic drugs.

Main Methods:

• Oral administration of compounds to hypercholesterolemic and normally fed weanling rats for four days.
• Automated analysis of total serum cholesterol and heparin precipitating lipoproteins (HPL).
• Calculation of the HPL:cholesterol ratio to identify hypobetalipoproteinemia.

Main Results:

• The screening method successfully identified compounds that specifically reduce HPL, leading to a decreased HPL:cholesterol ratio.
• Bicyclo (2.2.2)-octyloxyaniline (U-26328) exhibited hypobetalipoproteinemic activity.
• Familiar hypocholesterolemic agents, including clofibrates, nicotinic acid, and probucol, did not show similar specific HPL reduction.

Conclusions:

• A robust high-volume screening assay for hypobetalipoproteinemic agents has been developed.
• Bicyclo (2.2.2)-octyloxyaniline represents a potential therapeutic candidate for managing dyslipidemia.
• U-26328 demonstrates a distinct mechanism of action compared to conventional hypocholesterolemic drugs.